Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: Clin Pharmacol Ther. 2021 Jul 7;110(3):649–661. doi: 10.1002/cpt.2327

Figures 1A-C: — Survey respondent scores from implementers regarding pharmacogenomic evidence. For each of the 6 types of evidence listed on the X-axis, respondents were asked to rank how essential (A), how easy to interpret (B) and how available (C) that type of evidence is for clinical pharmacogenomic implementation on a scale from 0 to 100. The box and whisker plot shows the medians (horizontal lines within boxes), means (X), the interquartile ranges (boxes), the adjacent values (whiskers) and outliers (dots). RWE – real world evidence; FDA – Food and Drug Association.

Figures 1A-C: — Survey respondent scores from implementers regarding pharmacogenomic evidence. For each of the 6 types of evidence listed on the X-axis, respondents were asked to rank how essential (A), how easy to interpret (B) and how available (C) that type of evidence is for clinical pharmacogenomic implementation on a scale from 0 to 100. The box and whisker plot shows the medians (horizontal lines within boxes), means (X), the interquartile ranges (boxes), the adjacent values (whiskers) and outliers (dots). RWE – real world evidence; FDA – Food and Drug Association.